Colonial River Wealth Management LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)



Colonial River Wealth Management LLC raised its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 52.3% during the 1st quarter, Holdings Channel.com reports. The firm owned 20,988 shares of the biopharmaceutical company’s stock after buying an additional 7,206 during the quarter. Colonial River Wealth Management LLC’s holdings in Pfizer were worth $1,087,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Baltimore Washington Financial Advisors Inc. acquired a new stake in Pfizer in the fourth quarter worth about $290,000. PYA Waltman Capital LLC acquired a new stake in Pfizer in the fourth quarter worth about $31,000. Econ Financial Services Corp acquired a new stake in Pfizer in the fourth quarter worth about $31,000. Rinkey Investments acquired a new stake in shares of Pfizer during the fourth quarter worth about $32,000. Finally, Bivin & Associates Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth about $37,000. Institutional investors own 66.50% of the company’s stock.

In other Pfizer news, SVP Jennifer B. Damico sold 4,218 shares of the business’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total transaction of $227,603.28. Following the transaction, the senior vice president now owns 10,846 shares of the company’s stock, valued at $585,250.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jennifer B. Damico sold 4,000 shares of the business’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the transaction, the senior vice president now directly owns 15,064 shares in the company, valued at approximately $760,732. The disclosure for this sale can be found here. Insiders have sold 41,126 shares of company stock worth $2,075,003 in the last three months. 0.05% of the stock is currently owned by corporate insiders.

PFE has been the subject of a number of research reports. SVB Leerink initiated coverage on Pfizer in a report on Monday, May 23rd. They set a “market perform” rating and a $55.00 target price for the company. Barclays set a $52.00 target price on Pfizer in a report on Monday. The Goldman Sachs Group set a $51.00 target price on Pfizer in a report on Wednesday, May 25th. Wells Fargo & Company decreased their price target on Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. Finally, StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $57.26.

Shares of PFE opened at $50.66 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. Pfizer Inc. has a one year low of $38.82 and a one year high of $61.71. The stock has a market capitalization of $284.25 billion, a price-to-earnings ratio of 11.62, a PEG ratio of 0.63 and a beta of 0.76. The stock has a 50 day moving average price of $50.49 and a 200 day moving average price of $52.20.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. During the same quarter in the previous year, the firm posted $0.93 earnings per share. The firm’s revenue for the quarter was up 76.8% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 6.61 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.16%. The ex-dividend date of this dividend is Thursday, July 28th. Pfizer’s payout ratio is 36.70%.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)



Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Comment